The number of people treated with approved gene therapies and gene-modified cell therapies like CAR-T cancer treatments in the United States and Europe has reached more than 4,500, according to an estimate from the Alliance for Regenerative Medicine.<\/p>\n
The figure comes from the trade groups 2019 annual report, released Thursday. The alliance also reported that 1,066 clinical trials for gene therapies, cell therapies, and tissue engineering products were underway at the end of 2019. Regenerative medicine trials have room for more than 60,000 patients to enroll around the world.<\/p>\n
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!<\/p>\n
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.<\/p>\n
<\/p>\n
View post: The number of people treated with approved gene therapies and gene-modified cell therapies like CAR-T cancer treatments in the United States and Europe has reached more than 4,500, according to an estimate from the Alliance for Regenerative Medicine. Continue reading
\nGene and cell therapies continue growth in patients, financing, and costs - STAT<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"